Victor Maximov

Victor Maximov

Auto-generated profile, based on publicly available information

Victor Maximov

Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2013 in Journal of Cerebral Blood Flow & Metabolism
Verified
Journal Article
Open access
XYXiang Yun
Xiang Yun
VMVictor D Maximov
Victor D Maximov
JYJin Yu
Jin Yu
GZG Zhu
G Zhu
AVAlexey A Vertegel
Alexey A Vertegel
MKMark S Kindy
Mark S Kindy
Stroke is one of the major causes of death and disability in the United States. After cerebral ischemia and reperfusion injury, the generation of reactive oxygen species (ROS) and reactive nitrogen species may contribute to the disease process through alterations in the structure of DNA, RNA, proteins, and lipids. We generated various nanoparticles (liposomes, polybutylcyanoacrylate (PBCA), or poly(lactide-co-glycolide) (PLGA)) that contained active superoxide dismutase (SOD) enzyme (4,000 to 20,000 U/kg) in the mouse model of cerebral ischemia and reperfusion injury to determine the impact of these molecules. In addition, the nanoparticles were untagged or tagged with nonselective antibodies or antibodies directed against the N-methyl-D-aspartate (NMDA) receptor 1. The nanoparticles containing SOD protected primary neurons in vitro from oxygen-glucose deprivation (OGD) and limited the extent of apoptosis. The nanoparticles showed protection against ischemia and reperfusion injury when applied after injury with a 50% to 60% reduction in infarct volume, reduced inflammatory markers, and improved behavior in vivo. The targeted nanoparticles not only showed enhanced protection but also showed localization to the CA regions of the hippocampus. Nanoparticles alone were not effective in reducing infarct volume. These studies show that targeted nanoparticles containing protective factors may be viable candidates for the treatment of stroke.

3 June 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
VMVictor Maximov
Victor Maximov
ZCZhihong Chen
Zhihong Chen
YWYun Wei
Yun Wei
MRM. Hope Robinson
M. Hope Robinson
CHCameron J. Herting
Cameron J. Herting
AKAnna M. Kenney
Anna M. Kenney
Medulloblastoma, which is the most common malignant paediatric brain tumour, has a 70% survival rate, but standard treatments often lead to devastating life-long side effects and recurrence is fatal. One of the emerging strategies in the search for treatments is to determine the roles of tumour microenvironment cells in the growth and maintenance of tumours. The most attractive target is tumour-associated macrophages (TAMs), which are abundantly present in the Sonic Hedgehog (SHH) subgroup of medulloblastoma. Here, we report an unexpected beneficial role of TAMs in SHH medulloblastoma. In human patients, decreased macrophage number is correlated with significantly poorer outcome. We confirm macrophage anti-tumoural behaviour in both ex vivo and in vivo murine models of SHH medulloblastoma. Taken together, our findings suggest that macrophages play a positive role by impairing tumour growth in medulloblastoma, in contrast to the pro-tumoural role played by TAMs in glioblastoma, another common brain tumour.

1 April 2004 in Chemical Physics Letters
Verified
Journal Article
Closed access
YKYury V. Kolen'Ko
Yury V. Kolen'Ko
VMVictor D Maximov
Victor D Maximov
AGAlexei V Garshev
Alexei V Garshev
PMPavel E Meskin
Pavel E Meskin
NONikolai N Oleynikov
Nikolai N Oleynikov
BCBulat R Churagulov
Bulat R Churagulov

30 October 2019 in Brain
Verified
Journal Article
Open access
PDF file
CHCameron J Herting
Cameron J Herting
ZCZhihong Chen
Zhihong Chen
VMVictor Maximov
Victor Maximov
ADAlyssa Duffy
Alyssa Duffy
FSFrank Szulzewsky
Frank Szulzewsky
DHDolores Hambardzumyan
Dolores Hambardzumyan
Glioblastoma is the most common and uncompromising primary brain tumour and is characterized by a dismal prognosis despite aggressive treatment regimens. At the cellular level, these tumours are composed of a mixture of neoplastic cells and non-neoplastic cells, including tumour-associated macrophages and endothelial cells. Cerebral oedema is a near-universal occurrence in patients afflicted with glioblastoma and it is almost exclusively managed with the corticosteroid dexamethasone despite significant drawbacks associated with its use. Here, we demonstrate that dexamethasone blocks interleukin-1 production in both bone marrow-derived and brain resident macrophage populations following stimulation with lipopolysaccharide and interferon gamma. Additionally, dexamethasone is shown to inhibit downstream effectors of interleukin-1 signalling in both macrophage populations. Co-culture of bone marrow-derived macrophages with organotypic tumour slices results in an upregulation of interleukin-1 cytokines, an effect that is absent in co-cultured microglia. Genetic ablation of interleukin-1 ligands or receptor in mice bearing RCAS/tv-a-induced platelet-derived growth factor B-overexpressing glioblastoma results in reduced oedema and partial restoration of the integrity of the blood–brain barrier, respectively; similar to results obtained with vascular endothelial growth factor neutralization. We establish that tumours from dexamethasone-treated mice exhibit reduced infiltration of cells of the myeloid and lymphoid compartments, an effect that should be considered during clinical trials for immunotherapy in glioblastoma patients. Additionally, we emphasize that caution should be used when immune profiling and single-cell RNA sequencing data are interpreted from fresh glioblastoma patient samples, as nearly all patients receive dexamethasone after diagnosis. Collectively, this evidence suggests that interleukin-1 signalling inhibition and dexamethasone treatment share therapeutic efficacies and establishes interleukin-1 signalling as an attractive and specific therapeutic target for the management of glioblastoma-associated cerebral oedema.

1 December 2003 in Materials Science and Engineering: C
Verified
Journal Article
Closed access
YKYury V. Kolen'Ko
Yury V. Kolen'Ko
VMV.D Maximov
V.D Maximov
ABA.A Burukhin
A.A Burukhin
VMV.A Muhanov
V.A Muhanov
BCB.R Churagulov
B.R Churagulov

11 October 2010 in Biotechnology and Bioengineering
Verified
Journal Article
Closed access
PDF file
Vladimir ReukovVladimir Reukov
Vladimir Reukov
VMVictor Maximov
Victor Maximov
Alexey VertegelAlexey Vertegel
Alexey Vertegel